Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 8/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27906089 | 0.86 | LMNA (0.54) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL31387018 | 0.81 | KMT2A (0.47) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL9862017 | 0.80 | LMNA (0.51) | TSHRSMN1; SMN2LMNAKMT2ALIPE | |
| SCHEMBL6634752 | 0.79 | KMT2A (0.57) | LMNAKMT2ALIPEBCHEMAPT | |
| SCHEMBL10435427 | 0.79 | RAB9A (0.50) | TSHRSMN1; SMN2LMNAKMT2ALIPE | |
| SCHEMBL706407 | 0.79 | TSHR (0.63) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL30980818 | 0.79 | TSHR (0.63) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL16202054 | 0.77 | TSHR (0.47) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL3370461 | 0.76 | HPGD (0.67) | TSHRSMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL2737128 | 0.76 | TSHR (0.51) | TSHRSMN1; SMN2LMNAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | claimed |
| US-8088797-B2 | Substituted N-(4-cyano-1H-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041709-A1 | SUBSTITUTED N-(4-CYANO-1H-PYRAZOL-3-YL)METHYLAMINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | PRMT3, PRMT5, PRMT1 | TSHR 1491/4885SMN1; SMN2 742/4885LMNA 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.